{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:47:42Z","timestamp":1762782462159,"version":"3.40.5"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Primary pulmonary lymphoma (PPL) is a rare disease with not well\u2010defined optimal treatment. Outcomes and follow\u2010up are variable in published data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To define the outcome and optimal treatment strategies in PPL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed the medical records of 49 patients with PPL treated in three Italian Hematological Institutions between 2002 and 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010eight (77.5%) cases were indolent PPL, and 11 (22.5%) cases were aggressive PPL. The majority of patients were asymptomatic at diagnosis, early stages (stages IE\u2010IIE), normal serum LDH, no bone marrow involvement, and low or low\u2010intermediate risks of IPI. Local therapy\u00a0\u00b1\u00a0immunotherapy or immuno\u2010chemotherapy was possible in 18\/49 (37%) patients. Twenty\u2010eight (57%) patients were treated with immuno\u2010chemotherapy after biopsy. Waiting and watching were reported in 3 (6%) patients. Overall, the CR and ORR were 83.7% and 95.9%. With a median follow\u2010up of 62.5\u00a0months (range 0.8\u2010199\u00a0months), the estimated 5\u2010 and 10\u2010year OS rates were 85% and 72.3% for all patients, 89.2% and 80.3% for indolent PPL, and 70.7% and 47.1% for aggressive PPL. Aggressive PPL tended to have a high risk of progression in the first months (<jats:italic>P\u00a0<\/jats:italic>=\u00a0.056). No advantages were found for indolent PPL who received immuno\u2010chemotherapy or more conservative approaches.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our studies confirm the epidemiological and favorable survival of patients with PPL, suggesting a very conservative approach, particularly in indolent subtypes.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13507","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T02:34:33Z","timestamp":1597199673000},"page":"49-57","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment and prognosis of primary pulmonary lymphoma: A long\u2010term follow\u2010up study"],"prefix":"10.1111","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6979-8186","authenticated-orcid":false,"given":"Michelina","family":"Santopietro","sequence":"first","affiliation":[{"name":"Haematology and Haematopoietic Stem Cells Transplant Unit AO San Camillo\u2010Forlanini  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Kovalchuk","sequence":"additional","affiliation":[{"name":"Unit of Haematology AOU Careggi  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Battistini","sequence":"additional","affiliation":[{"name":"Haematology and Haematopoietic Stem Cells Transplant Unit AO San Camillo\u2010Forlanini  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[{"name":"Unit of Haematology AOU Careggi  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[{"name":"Unit of Haematology and Stem Cell Transplantation Campus Bio\u2010Medico University  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Romano","sequence":"additional","affiliation":[{"name":"Unit of Haematology AOU Careggi  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Zoli","sequence":"additional","affiliation":[{"name":"Haematology and Haematopoietic Stem Cells Transplant Unit AO San Camillo\u2010Forlanini  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Avvisati","sequence":"additional","affiliation":[{"name":"Unit of Haematology and Stem Cell Transplantation Campus Bio\u2010Medico University  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[{"name":"Unit of Haematology AOU Careggi  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[{"name":"Haematology and Haematopoietic Stem Cells Transplant Unit AO San Camillo\u2010Forlanini  Rome Italy"},{"name":"Unit of Haematology AOU Careggi  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00404102"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197201)29:1<252::AID-CNCR2820290138>3.0.CO;2-#"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(99)01535-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000090"},{"key":"e_1_2_8_6_1","first-page":"2065","article-title":"Primary pulmonary MALT lymphoma \u2013 Case report and literature overview","volume":"20","author":"Nahorecki A","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00039309"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2016140339"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcl.2016.03.002"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/16420165"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2005.04.014"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1179\/102453311X12940641877722"},{"volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008","author":"Swerdlow SH","key":"e_1_2_8_13_1"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12730"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2019.01.009"},{"key":"e_1_2_8_18_1","first-page":"2082","article-title":"Diagnostic and prognostic factors for patients with primary pulmonary non\u2010Hodgkin's lymphoma: a 16\u2010years single center retrospective study","volume":"18","author":"Quian J","year":"2019","journal-title":"Oncology Letters"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.04.004"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2042-z"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2683"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1694-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6272"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.6994"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2243"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1179\/1607845412Y.0000000031"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13507","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T10:32:59Z","timestamp":1693823579000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/ejh.13507"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13507","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"2020-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}